Analyst Price Targets — CRVO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 20, 2026 10:39 am | — | Roth Capital | $7.00 | $2.71 | TheFly | CervoMed price target lowered to $7 from $9 at Roth Capital |
| May 18, 2026 9:34 pm | — | Roth Capital | $9.00 | $3.04 | TheFly | CervoMed price target lowered to $9 from $11 at Roth Capital |
| November 5, 2025 11:14 am | Raghuram Selvaraju | H.C. Wainwright | $25.00 | $7.02 | TheFly | CervoMed upgraded to Buy from Neutral at H.C. Wainwright |
| October 17, 2025 10:25 am | — | Roth Capital | $20.00 | $7.60 | TheFly | CervoMed price target raised to $20 from $16 at Roth Capital |
| August 12, 2025 11:59 am | Boobalan Pachaiyappan | Roth Capital | $16.00 | $9.41 | TheFly | CervoMed price target lowered to $16 from $20 at Roth Capital |
| September 18, 2024 5:17 am | Danill Gataulin | Loop Capital Markets | $16.32 | $4.79 | StreetInsider | Chardan Capital Markets Starts CervoMed (CRVO) at Buy |
| September 18, 2024 5:05 am | Daniil Gataulin | Chardan Capital | $16.32 | $4.79 | TheFly | CervoMed initiated with a Buy at Chardan |
| April 8, 2024 7:06 am | Sumant Kulkarni | Canaccord Genuity | $19.29 | $6.08 | StreetInsider | CervoMed (CRVO) PT Raised to $65 at Canaccord Genuity |
Latest News for CRVO
Prioritizing strategic partnership to advance neflamapimod into Phase 3 for the treatment of dementia with Lewy bodies (DLB) Neflamapimod awarded Innovation Passport Designation under the United Kingdom's Innovative Licensing and Access Pathway (ILAP) for development in DLB New analyses presented at the Alzheimer's Association International Conference (AAIC) 2026 reinforce neflamapimod's treatment effect in pure DLB…
BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the Canaccord Genuity 46th Annual Growth Conference, being held in Boston, MA, on Tuesday, August 11, 2026. During…
Innovation Passport award designed to support accelerated time to market and help expedite patient access to potentially transformative new investigational medicines
BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
Interim biomarker data accepted for presentation at the 19 th Clinical Trials on Alzheimer's Disease (CTAD) conference
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CRVO.
U.S. House Trading
No House trades found for CRVO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.